Reaction
Optic Ischaemic Neuropathy reporting signals
As of the last recalculation, Optic Ischaemic Neuropathy appears in 3,512 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is ORAL SEMAGLUTIDE (PRR 61.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Oral Semaglutide | 631 | 61.9 | 62.4 |
| Sildenafil Citrate | 551 | 30.2 | 30.4 |
| Amiodarone Hydrochloride | 37 | 19.8 | 19.8 |
| Sildenafil | 90 | 9.4 | 9.4 |
| Sildenafil Powder, | 52 | 8.8 | 8.8 |
| Quinine | 12 | 8.3 | 8.3 |
| Tadalafil | 134 | 8.2 | 8.2 |
| Testosterone | 30 | 7.7 | 7.7 |
| Tirzepatide | 150 | 5.7 | 5.7 |
| Sumatriptan Succinate | 22 | 5.2 | 5.2 |
| Faricimab | 6 | 4.4 | 4.4 |
| Metformin Hydrochloride | 43 | 4.3 | 4.3 |
| Bevacizumab | 88 | 4.3 | 4.3 |
| Metformin Hydrochloride Tablets | 41 | 4.3 | 4.3 |
| Metformin Hydrochloride Extended-Release Tablets | 41 | 4.3 | 4.3 |
| Metformin Hydrochloride Tablet | 41 | 4.3 | 4.3 |
| Pemetrexed | 14 | 3.9 | 3.9 |
| Ranibizumab | 17 | 3.8 | 3.8 |
| Ribavirin | 35 | 3.2 | 3.2 |
| Dapagliflozin | 16 | 3.0 | 3.0 |
| Durvalumab | 10 | 2.9 | 2.9 |
| Etoposide | 34 | 2.8 | 2.8 |
| Travoprost | 4 | 2.7 | 2.7 |
| Aflibercept | 14 | 2.7 | 2.7 |
| Liraglutide | 22 | 2.6 | 2.7 |
| Pemetrexed Disodium | 16 | 2.5 | 2.5 |
| Sofosbuvir | 8 | 2.4 | 2.4 |
| Dabrafenib | 8 | 2.3 | 2.3 |
| Loratadine And Pseudoephedrine Sulfate | 3 | 2.2 | 2.2 |
| Pseudoephedrine Hcl | 4 | 2.2 | 2.2 |
| Dulaglutide | 30 | 2.0 | 2.0 |
| Peginterferon Alfa-2A | 16 | 1.8 | 1.8 |
| Pseudoephedrine Hydrochloride | 3 | 1.7 | 1.7 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 1.6 | 1.6 |
| Diroximel Fumarate | 3 | 1.5 | 1.5 |